Sinovac Biotech Ltd. Reports Strong Sales Growth for Healive and Advances Multiple Vaccine Initiatives

Strategic Insights -

Sinovac Biotech Ltd. (SVA) has been experiencing significant growth in the sales of its hepatitis A vaccine, Healive, with domestic Chinese sales reaching approximately US$6.5 million for the year ended December 31, 2004, more than 2 times the sales from 2003. This growth is a testament to the increasing demand for Healive in the Chinese market. Additionally, Sinovac received final approval for the marketing and sales of its combined hepatitis A and B vaccine, Bilive, in January 2005, marking a significant milestone in the company's product portfolio. Bilive is the first combined inactivated hepatitis A and B vaccine developed by Chinese scientists.

Key Takeaways:

  • Sinovac Biotech Ltd. (SVA) reported strong sales growth of its hepatitis A vaccine, Healive, with US$6.5 million in domestic Chinese sales for the year ended December 31, 2004, more than 2 times 2003 sales.
  • Sinovac received final approval for the marketing and sales of its combined hepatitis A and B vaccine, Bilive, in January 2005, marking its first combined inactivated hepatitis A and B vaccine developed by Chinese scientists.
  • China has been significantly affected by viral hepatitis, with approximately 50-70% of its 1.3 billion citizens infected with the hepatitis B virus at some point in their lives.
  • Sinovac has launched marketing of Bilive and expects to record its first sales in May 2005.
  • The company's split flu vaccine received approval of its new drug certificate in February 2005, with final approval for sales expected in 2005 after GMP certification.
  • Sinovac's SARS vaccine induced SARS-neutralizing antibodies in phase 1 clinical trial, delivering a positive outcome.
  • The company is co-developing a human vaccine targeting the avian flu virus in partnership with the China Center of Disease Control (CDC).
  • Sinovac specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and B, influenza, SARS, and avian flu.

Statistics:

  • US$6.5 million in domestic Chinese sales for Healive in 2004
  • 50-70% of China's 1.3 billion citizens infected with hepatitis B virus at some point in their lives
  • 210 days observation period for SARS phase 1 clinical trial

Sources:

  • Sinovac Biotech Ltd.
  • Health & Medicine Week editors
  • China's SFDA (State Food and Drug Administration)
  • U.S. FDA (Food and Drug Administration)
  • NewsRx.com
  • China Center of Disease Control (CDC)